Status:
ACTIVE_NOT_RECRUITING
Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
Lead Sponsor:
NGM Biopharmaceuticals, Inc
Collaborating Sponsors:
Merck Sharp & Dohme LLC
Conditions:
Mesothelioma
Glioblastoma
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
Study of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
Eligibility Criteria
Inclusion
- Histologically or cytologically documented locally advanced or metastatic solid tumor malignancy.
- Progressed or was intolerant to all available therapies known to confer clinical benefit appropriate for their tumor type, and for which the patient was eligible and willing to receive, or refused SOC treatments that are perceived to have marginal clinical benefit.
- Adequate bone marrow, kidney and liver function.
- Performance status of 0 or 1.
- Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade 1 except for AEs not constituting a safety risk by Investigator judgement.
Exclusion
- Prior treatment targeting ILT2 and/or ILT4 or targeting HLA-G.
Key Trial Info
Start Date :
June 9 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2025
Estimated Enrollment :
179 Patients enrolled
Trial Details
Trial ID
NCT04913337
Start Date
June 9 2021
End Date
July 1 2025
Last Update
October 2 2024
Active Locations (27)
Enter a location and click search to find clinical trials sorted by distance.
1
NGM Clinical Study Site
Los Angeles, California, United States, 90033
2
NGM Clinical Study Site
Newport Beach, California, United States, 92663
3
NGM Clinical Study Site
Santa Monica, California, United States, 90404
4
NGM Clinical Study Site
Santa Rosa, California, United States, 94505